PD-1+CD8+ T cells were activated rather than exhausted. PD-1+CD8+ T cells infiltrated muscle tissues. Affected muscles reacted to IFNγ, which could be produced from effector T cells, as a danger ...
Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. The authors of a new article published in Acta Pharmaceutica Sinica B describe ...
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today ...
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback